GH Research PLC

FRC's fair value estimate for GH Research PLC, and the rating behind it. GHRS last traded at $19.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for GH Research PLC. Starting points for GH Research PLC: EPS -$0.94, beta 1.32 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for GH Research PLC. GH Research PLC does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for GH Research PLC. Trailing twelve-month EPS for GH Research PLC stands at -$0.94. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for GH Research PLC. GH Research PLC has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

GH Research PLC valued side by side against its closest peers. GH Research PLC is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold GH Research PLC, and how their positions are changing. At a $1.32B market value, institutional positions materially move GH Research PLC's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by GH Research PLC executives and directors. Shares of GH Research PLC have traded between $6.72 and $20.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming GH Research PLC. GH Research PLC is a $1.32B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming GH Research PLC. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for GH Research PLC. Coverage tracks GH Research PLC within Biotechnology (Healthcare). Press releases and market coverage, newest first.